文献速递炎症性肠病

结肠组织4基因表达水平或可预测IBD患者维多珠单抗内镜缓解

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-08-22

研究对31例接受维多珠单抗和20例接受TNF拮抗剂的IBD患者结肠活检行RNA测序,比较内镜缓解与未缓解者的基因表达。发现44个基因表达有显著差异,PIWIL1、MAATS1、RGS13、DCHS2基线表达预测维多珠单抗内镜缓解训练集准确率80%、验证集1准确率100%,3个独立数据集验证P=.003,且与抗TNF应答无关。

要点

  • 基线结肠组织4基因表达可预测维多珠单抗内镜缓解,训练集准确率80%、验证集1准确率100%。
  • 该4基因表达与抗TNF药物应答无关。
  • 未缓解者结肠组织白细胞迁移显著增加(P<.006),单核细胞、M1巨噬细胞、CD4+ T细胞富集。

核心结论

  • IBD患者结肠组织基线4基因(PIWIL1、MAATS1、RGS13、DCHS2)表达水平与维多珠单抗治疗后内镜缓解相关,但与抗TNF药物应答无关。
  • 该基因特征在4个独立数据集中验证,并在蛋白水平得到免疫组化确认。

研究设计与样本

  • 获取开始维多珠单抗治疗(n=31)或TNF拮抗剂治疗(n=20)的IBD患者炎症结肠活检,行RNA测序分析。
  • 比较内镜缓解与未缓解患者基因表达模式,并进行通路分析和细胞解卷积,分为训练集(n=20)和验证集(n=11)。
  • 用3个独立数据集(n=66)验证与维多珠单抗内镜缓解相关的基线基因表达模式,并行免疫组化分析。

主要发现

  • 维多珠单抗治疗后缓解与未缓解患者间44个基因表达水平有显著差异;未缓解者结肠组织白细胞迁移显著增加(P<.006)。
  • 解卷积方法显示未缓解者结肠组织单核细胞(P=.005)、M1巨噬细胞(P=.05)、CD4+ T细胞(P=.008)显著富集,缓解者治疗前naïve B细胞数量较高(P=.05)。
  • PIWIL1、MAATS1、RGS13、DCHS2基线表达水平区分维多珠单抗内镜缓解与未缓解,训练集准确率80%,验证数据集1准确率100%。
  • 3个独立数据集通过微阵列、RNA测序和定量PCR分析验证上述发现(P=.003)。
  • 这4个基因表达水平与抗TNF药物应答无关;免疫组化确认mRNA编码蛋白的存在。

关键数值与推荐

  • 内镜缓解定义:克罗恩病患者第6个月无溃疡;溃疡性结肠炎患者第14周Mayo内镜亚评分≤1。
  • 训练集准确率80%,验证数据集1准确率100%,3个独立数据集验证P=.003。
  • 未缓解者白细胞迁移增加P<.006;单核细胞P=.005、M1巨噬细胞P=.05、CD4+ T细胞P=.008富集;缓解者naïve B细胞P=.05。

临床怎么用

  • 基线结肠组织4基因表达水平可能用于预测IBD患者维多珠单抗治疗后内镜缓解。
  • 该4基因表达水平与抗TNF药物应答无关,或有助于区分维多珠单抗与抗TNF治疗选择。
  • 这些基因的研究可能为维多珠单抗作用机制提供见解。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy. METHODS: We obtained biopsies from inflamed colon of patients with IBD who began treatment with vedolizumab (n = 31) or tumor necrosis factor (TNF) antagonists (n = 20) and performed RNA-sequencing analyses. We compared gene expression patterns between patients who did and did not enter endoscopic remission (absence of ulcerations at month 6 for patients with Crohn's disease or Mayo endoscopic subscore ≤1 at week 14 for patients with ulcerative colitis) and performed pathway analysis and cell deconvolution for training (n = 20) and validation (n = 11) datasets. Colon biopsies were also analyzed by immunohistochemistry. We validated a baseline gene expression pattern associated with endoscopic remission after vedolizumab therapy using 3 independent datasets (n = 66). RESULTS: We identified significant differences in expression levels of 44 genes between patients who entered remission after vedolizumab and those who did not; we found significant increases in leukocyte migration in colon tissues from patients who did not enter remission (P < .006). Deconvolution methods identified a significant enrichment of monocytes (P = .005), M1-macrophages (P = .05), and CD4+ T cells (P = .008) in colon tissues from patients who did not enter remission, whereas colon tissues from patients in remission had higher numbers of naïve B cells before treatment (P = .05). Baseline expression levels of PIWIL1, MAATS1, RGS13, and DCHS2 identified patients who did vs did not enter remission with 80% accuracy in the training set and 100% accuracy in validation dataset 1. We validated these findings in the 3 independent datasets by microarray, RNA sequencing and quantitative PCR analysis (P = .003). Expression levels of these 4 genes did not associate with response to anti-TNF agents. We confirmed the presence of proteins encoded by mRNAs using immunohistochemistry. CONCLUSIONS: We identified 4 genes whose baseline expression levels in colon tissues of patients with IBD associate with endoscopic remission after vedolizumab, but not anti-TNF, treatment. We validated this signature in 4 independent datasets and also at the protein level. Studies of these genes might provide insights into the mechanisms of action of vedolizumab.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Verstockt B, Verstockt S, Veny M, et al. Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 31446181. doi:10.1016/j.cgh.2019.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。